Episode 290: The ChemoCentryx Saga With Anish Koka

Cardiologist and “The Doctor's Lounge” host Anish Koka, MD, joins the show to examine the extraordinary ChemoCentryx and Tavneos (avacopan) controversy, including the retraction of a New England Journal of Medicine clinical trial that played a key role in the drug's FDA approval for ANCA-associated vasculitis. Based on his Substack investigation, Dr. Koka breaks down the timeline of events, the concerns surrounding post hoc changes to trial endpoints, the FDA's response, and the far-reaching implications for clinical trial integrity, drug development, pharmaceutical regulation, and evidence-based medicine. Tune in for a thought-provoking discussion on scientific transparency, regulatory oversight, and what this high-profile case means for physicians, researchers, the pharmaceutical industry, and patients alike.Read the substack article.https://anishkokamd.substack.com/p/we-cannot-afford-to-miss-a-superioritySubscribe to The Doctor's Lounge.https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. https://www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. https://www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA